In Vivo Biotransformations of Antibody–Drug Conjugates
Authors:
- 30 July 2015
- journal article
- review article
- Published by Taylor & Francis in Bioanalysis
- Vol. 7 (13) , 1649-1664
Abstract
The selective delivery of potent pharmacologically active compounds to target tissue or cells by antibody–drug conjugates makes this immuno-conjugate a promising modality for the treatment of cancers. A thorough understanding of the structural integrity of the linker, the payload and the conjugation site during biological exposure is critical throughout the process of novel linker-payload design and optimization of PK profile. This understanding is a key aspect of the effort to maximize efficacy while minimizing toxicity in preclinical testing and to ensure the translation to the clinical setting. The complexity of this bioconjugate modality is a source of significant challenge for analytical interrogation and analysis in vivo. Therefore, we report herein a survey of various types of biotransformation events that have been elucidated in recent years.Keywords
This publication has 67 references indexed in Scilit:
- Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody TherapeuticsThe AAPS Journal, 2012
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesNature Biotechnology, 2012
- Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid ConjugatesJournal of Medicinal Chemistry, 2011
- Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide LinkageBioconjugate Chemistry, 2011
- Design of Antibody−Maytansinoid Conjugates Allows for Efficient Detoxification via Liver MetabolismBioconjugate Chemistry, 2011
- Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to MicrotubulesMolecular Cancer Therapeutics, 2010
- Fundamental Relationships between Structure, Reactivity, and Biological Activity for the Duocarmycins and CC-1065Journal of Medicinal Chemistry, 2009
- Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug SelectionCancer Research, 2009
- Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Erratum: Development of potent monoclonal antibody auristatin conjugates for cancer therapyNature Biotechnology, 2003